Skip to main content
MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
10.22
+0.21 (2.14%)
At close: Nov 11, 2026, 4:00 PM EST
10.22
0.00 (-0.04%)
Pre-market: Nov 12, 2026, 6:35 AM EST

MiNK Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
6.626.734.317.437.834.64
Research & Development
5.755.766.3415.4923.1213.97
Other Operating Expenses
-0.380.150.64---
Operating Expenses
11.9912.6411.2922.9230.9518.61
Operating Income
-11.99-12.64-11.29-22.92-30.95-18.61
Interest Expense
------2.43
Interest & Investment Income
0.320.180.170.460.25-
Currency Exchange Gain (Loss)
0.34-----0.41
Other Non Operating Income (Expenses)
-0.03-0.030.15-0-0.090.63
EBT Excluding Unusual Items
-11.36-12.49-10.97-22.46-30.78-20.82
Gain (Loss) on Sale of Assets
--0.19---
Other Unusual Items
----2.79-9.4
Pretax Income
-11.36-12.49-10.78-22.46-27.99-30.21
Net Income
-11.36-12.49-10.78-22.46-27.99-30.21
Net Income to Common
-11.36-12.49-10.78-22.46-27.99-30.21
Net Income Growth
------
Shares Outstanding (Basic)
544333
Shares Outstanding (Diluted)
544333
Shares Change
19.52%13.18%9.82%2.04%29.38%7.95%
EPS (Basic)
-2.40-2.93-2.86-6.54-8.31-11.61
EPS (Diluted)
-2.40-2.93-2.86-6.54-8.31-11.61
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-6.83-5.93-9.56-15.84-19.12-13.08
Free Cash Flow Per Share
-1.44-1.39-2.53-4.61-5.68-5.02
EBITDA
-11.83-12.46-11.07-22.72-30.83-18.53
D&A For EBITDA
0.150.180.220.20.120.08
EBIT
-11.99-12.64-11.29-22.92-30.95-18.61
SEC Filings: 10-K · 10-Q